Quest Diagnostics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while Vanguard Real Estate Index Fund ETF trades at $90.49 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 2.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| DGX | VNQ | |
|---|---|---|
Market Cap | $25.48B | $70.80B |
Volume | 941,866 | 6,073,580 |
Sector | Health | — |
52-Week High | $247.45 | $100.95 |
52-Week Low | $173.49 | $87.00 |
Typical Hold Time | 56 Days | 113 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
VNQ trades at $90.50, up 2.04% today but facing a bearish technical trend with key support at $87. The ETF's fundamentals are obscured by missing valuation ratios, while sentiment is mixed amid rising interest rates pressuring REIT yields. Recent news highlights institutional buying but also concerns over dividend sustainability versus Treasury bills.
Outlook remains cautious due to interest rate sensitivity and sector oversupply risks. Opportunities exist for contrarian investors seeking long-term real estate exposure, but near-term headwinds from Fed policy and economic volatility warrant careful risk assessment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →